Labiotech.eu

News and Trends 11 Dec 2015

Digital CRISPR Cloud Services: An Appealing Product to Big Bioinformatics Investors like Illumina

London’s Desktop Genetics and their remote CRISPR and digital genetics platform has caught the eye of US Illumina – the US Competitor to German Giant QIAGEN in Next Generation Sequencing (NGS)… Desktop Genetics (DeskGen) is an online service that researchers can use to design CRISPR gene editing experiments, purchase reagents and find commercial entities to […]

December 11, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Dec 2015

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

This week we say farewell to Zurich and head North, through Germany where we arrive at our next destination, the capital city of Denmark, Copenhagen. This amazing city is famous for the Little Mermaid Statue, the autonomous neighborhood of Christiania and Tivoli Gardens Amusement Park. It is also home to our biotech of the week: Zealand […]

December 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Dec 2015

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Pneumonia, Meningitis and Sepsis: All these potentially fatal infections could one day be vaccinated against with Cambridge’s ImmBio and their Pneumococcal vaccine, which has now started safety & tolerability trials in the UK. ImmBio is based at the Babraham Institute, a unit of the UK’s Biotechnology & Biological Sciences Research Council (and in our Listed […]

December 10, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Dec 2015

Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis

Peanut allergy in children can be life-threatening, with safe treatment options available. Now DBV Technologies in Paris has a phase III transdermal patch which desensitizes the patient to peanuts, with fast-track FDA approval. The allergens in peanuts can stimulate an immune response to their presence, which can even result in life-threatening anaphylaxis (here is a […]

December 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Dec 2015

“Structural Biology is changing the way we design drugs”

Structural biology, the study of the structure of biological macromolecules, is becoming a real asset in the drug development process. The PSDI meeting is THE not-to-be-missed event for the experts in this field. Labiotech.eu gives you a glimpse of the last trends discussed during this conference thanks to our exclusive interview with Dr Peter Reinemer, […]

December 10, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

Here are the 6 Healthcare Disruptors We met in Paris

How can and will Healthcare be disrupted? This is an important question addressed at an event on Differential Medicine at ‘TheFamily‘ VC in Paris. On the 3rd and 4th December, I attended the Differential Medicine conference in Paris at the ‘The Family‘ HQ (an entrepreneurial VC). Here I give an overview of some of the […]

December 9, 2015 - 6 minutesmins - By Julie Lellouche

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this […]

December 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Digital CRISPR Cloud Services: An Appealing Product to Big Bioinformatics Investors like Illumina

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis

“Structural Biology is changing the way we design drugs”

Infographic: The Anatomy of European Biotech

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Here are the 6 Healthcare Disruptors We met in Paris

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!